Department of Molecular Physiology & Biophysics

University of Iowa


Henry Lab Publications


Barnes, J.M., Nauseef, J.T. and Henry, M.D. Resistance to fluid shear stress is a conserved biophysical property of malignant cells. PLoS One, In press, 2012. Varzavand, A., Drake, J.M., Svensson, R.U., Herndon, M.E., Zhou, B., Henry, M.D., Stipp C. Integrina3b1 regulates tumor cell responses to stromal cells and can function to suppress prostate cancer metastatic colonization. Clin. Exp. Metastasis, In press, 2012. Norian L.A., Kresowik T.P., Rosevear H.M., James B.R., Rosean T.R., Lightfoot A.J., Kucaba T.A., Schwarz C., Weydert C.J., Henry M.D., Griffith T.S. Eradication of metastatic renal cell carcinoma after adenovirus-encoded TNF-related apoptosis-inducing ligand (TRAIL)/CpG immunotherapy. PLoS One.


Tang X., Sun Z., Runne C., Madsen J., Domann F., Henry M., Lin F., and Chen S. A critical role of G in tumorigenesis and metastasis of breast cancer. J. Biol. Chem., 286:13244-54, 2011. Nelson, E.S., Folkmann, A.W., Henry, M.D., DeMali, K.A. Vinculin activators target Integrins from within the cell to increase melanoma sensitivity to chemotherapy. Mol.Cancer Res. 2011 Apr 19. [Epub ahead of print]. Svensson, R.U., Haverkamp, J.M., Thedens, D.R., Cohen, M.B., Ratliff, T.L., and Henry, M.D. Slow disease progression in a C57BL/6 Pten deficient mouse model of prostate cancer. Am. J. Pathol., 179(1):502-12, 2011. Yong, T., Sun, A., Henry, M.D., Meyers, S., and Davis, J.N. Down Regulation of CSL Inhibits Cell Proliferation in Prostate and Breast Cancer Cells. J. Cell. Biochem. 2011 Apr 25. doi: 10.1002/jcb.23157. [Epub ahead of print]. Muniz, V.P, Barnes, J.M., Paliwal, S., Xhang, X., Tang, X, Chen, S., Zamba, K.D., Cullen, J.J., Myerholz, D.K., Meyers, S., Davis, J.N., Grossman, S.R., Henry, M.D. and Quelle, D. E. The ARF tumor suppressor inhibits tumor cell colonization independent of p53 in a novel mouse model of pancreatic ductal adenocarcinoma metastasis. Mol. Cancer Res., 9(7):867-77, 2011. Nauseef, J.T. and Henry, M.D. Epithelial-to-mesenchymal transition in prostate cancer: Paradigm or puzzle? Nature Reviews Urology 8(8):428-39, 2011. Barnes, J.M. and Henry, M.D. Cellular and Molecular Biology of Cancer Cell Extravasation. In Signaling pathways and molecular mediators in metastasis. Springer. In Press 2011.


Esser, A.K., Cohen, M.B. and Henry, M.D. Dystroglycan is not required for maintenance of the luminal epithelial basement membrane or cell polarity in the mouse prostate. Prostate, 70:777-787, 2010. Drake, J.M., Danke, J.R. and Henry, M.D. Bone-Specific Growth Inhibition of Prostate Cancer Metastasis by Atrasentan. Cancer Biol. and Ther., 9:607-614, 2010. Commentary: pp. 615-617. Drake, J.M., Barnes J.M., Madsen J.M., Domann F.E., Stipp C.S. and Henry, M.D. ZEB1 coordinately regulates laminin-332 and 4 integrin expression altering the invasive phenotype of prostate cancer cells. J. Biol. Chem., 285:33940-8, 2010 Reviewed by Faculty of 1000 Biology Haverkamp J.M., Charbonneau B., Myerholtz D. K., Cohen M.B., Snyder P.D., Svensson R.U., Henry M.D., Wang H.-H., and Ratliff T.L. Characterization of an inducible mouse model of abacterial prostatitis.Prostate, 2010 Jan 12. [Epub ahead of print].


Weydert, C.J., Esser, A.K., Mejia, R.A., Drake, J.M., Barnes, J.M., Henry, M.D. Endothelin-1 inhibits prostate cancer growth in vivo through vasoconstriction of tumor-feeding arterioles. Cancer Biol. and Ther., 8:62-71, 2009. Cover Article. Beltran-Valero de Bernabe, D., Inamori, K., Moriguchi, T., Weydert, C.J., Harper, H.A., Willer, T., Henry, M. D., Campbell, K.P. Loss of alpha-dystroglycan laminin-binding in epithelium derived cancers is caused by silencing of LARGE. J. Biol. Drake, J.M., Strohbehn, G.S., Bair, T.B., Moreland, J.G., Henry, M.D. ZEB1 enhances transendothelial migration and represses the epithelial phenotype of prostate cancer cells. Mol. Biol. Cell, 20:2207-2217, 2009.


Svensson, R.U., Shey, M.R., Ballas, Z.K., Dorkin, J.R., Goldberg, M., Akinc, A., Langer, R., Anderson, D.G., Bumcrot, D. and Henry, M.D. Assessing siRNA pharmacodynamics in a luciferase-expressing mouse. Molecular Therapy, 16:1995-2001, 2008.


Svensson, R.U., Barnes, M.J. Rokhlin, O., Cohen, M.B. and Henry, M.D. Chemotherapeutic Agents Upregulate the CMV Promoter via p38 MAPK: Implications for Bioluminescence Imaging of Tumor Response to Therapy. Cancer Research, 67:10445-10454 , 2007.


Weir, M.L., Oppizzi, M.L., Henry, M.D., Onishi, A., Campbell K.P., Bissell, M.J. and Muschler, J. Dystroglycan loss disrupts polarity and beta-casein induction in mammary epithelial cells by perturbing laminin anchoring. J Cell Sci. 119:4047-4058, 2006. Wang, G., Cong, W., Kumar, D., Qian, X., Shen, H., Sinn, P.,Hoffman, E., McLennan, G., and Henry, M. In vivo mouse studies with bioluminescence tomography. Optics Express, 14:7801-7809, 2006.


Henry, M.D, Silva, M.D., Wen, S., Siebert, E. Solin, E., Chandra, S., Worland, P.J. Spiculated periosteal response induced by intraosseous injection of 22Rv1 prostate cancer cells resembles subset of bone metastases in prostate cancer patients.Prostate, 65:347-354, 2005. Kanagawa, M., Michele D.E., Satz, J.S., Barresi R., Kusano, H., Sasaki, T., Timpl, R.,Henry, M.D. and Campbell, K.P. Disruption of perlecan binding and matrix assembly by post translational or genetic disruption of dystroglycan function. FEBS Lett., 579:4792-4796, 2005. Drake, J.M., Gabriel, C L. and Henry, M.D. Assessing tumor growth and distribution in a model of prostate cancer metastasis using bioluminescence imaging. Clin. Exp. Metastasis, 22:674-684, 2005.